A new Joslin Diabetes Center-led study has shown conclusively that a neuropeptide, melanin concentrating hormone (MCH), found in the brain and known for its role in increasing appetite in people, plays a role in the growth of insulin-producing beta cells and the secretion of insulin. This finding has the potential to spur the development of new treatments for diabetes that stimulate the production of insulin-producing beta cells in the pancreas. This latest research, conducted with researchers at Beth Israel Deaconess Medical Center in Boston and other institutions, will appear in the February 2007 issue of Diabetes.
An earlier Joslin-led study examined the connection between obesity and MCH, which plays a critical role in energy balance and appetite, observing an increase in the number of beta cells when MCH levels are high. This was a new finding that had not been observed before. Although MCH’s role in appetite control is well known, its effects on the secretion of endocrine hormones has not been fully understood.
“It’s a very logical connection,” says Rohit N. Kulkarni, M.D., Ph.D., investigator at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School, who led the study. “Whenever you eat food, your body needs more insulin. When MCH induces appetite, it simultaneously increases insulin secretion from beta cells and enhances growth of beta cells. If the proteins that mediate the growth mechanism can be identified, it could lead to the development of new drugs that would enhance beta cell growth to treat type 1 and type 2 diabetes.”
In type 1 diabetes (insulin-dependent) diabetes, which accounts for 5 to 10 percent (between 700,000 and 1.4 million people) of diabetes cases in the United States, an autoimmune process has destroyed the insulin-producing islet cells in the pancreas. In type 2 diabetes, the far more common form of the disease, the body doesn’t produce enough insulin and/or can’t use insulin properly (insulin resistance). Both diseases could benefit from treatments that stimulate beta cells in the pancreas to produce insulin.
In the first study, in which mice were genetically engineered to over-express MCH, Dr. Kulkarni and his colleagues observed changes in beta cell mass out of proportion with the degree of obesity, suggesting that MCH had a direct effect on islets. To build on these previous findings, the researchers focused this study on gaining a deeper understanding of how MCH and its receptors influence growth of beta cells.
The investigators first confirmed that MCH and its receptors are indeed expressed in islet cells of mice and humans. They then treated human donor or mouse pancreatic islet cells with MCH and found that it increased insulin secretion, compared to islet cells without MCH, which did not show the same effect.
In the next phase, the researchers examined genetically-engineered mice that did not produce MCH and consequently had abnormally small islets. “This indicated to us that MCH is important for growth of islets,” says Dr. Kulkarni.
The next step in the research process is to pinpoint exactly how MCH is regulating the growth of beta cells and identify which proteins are involved in this growth process. “We know MCH is having an effect on both growth and function likely by recruiting different proteins. It will be worth exploring which proteins are being activated by MCH to cause the growth effect,” Dr. Kulkarni explains.
A follow-up study has been designed and is currently awaiting funding. It will look at how MCH interacts with glucagon-like peptide 1 (GLP-1), a hormone involved in beta cell growth. An analogue of GLP-1 hormone has already been approved by the FDA for treating type 2 diabetes. The goal is to understand how GLP-1 and MCH can work together to promote beta cell growth.
Marjorie Dwyer | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences
20.01.2017 | Life Sciences